References
- Gamaletsou MN, Kontoyiannis DP, Sipsas NV, Moriyama B, Alexander E, Roilides E, et al. Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011). Clin Infect Dis 2012;55:1338–51.
- Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503–35.
- Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012;18(Suppl 7):19–37.
- Harmsen S, McLaren AC, Pauken C, McLemore R. Amphotericin B is cytotoxic at locally delivered concentrations. Clin Orthop Relat Res 2011;469:3016–21.
- Slenker AK, Keith SW, Horn DL. Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature. Diagn Microbiol Infect Dis 2012; 73:89–93.
- Azzam K, Parvizi J, Jungkind D, Hanssen A, Fehring T, Springer B, et al. Microbiological, clinical, and surgical features of fungal prosthetic joint infections: a multi-institutional experience. J Bone Joint Surg Am 2009;91(Suppl 6):142–9.
- Anagnostakos K, Kelm J, Schmitt E, Jung J. Fungal periprosthetic hip and knee joint infections clinical experience with a 2-stage treatment protocol. J Arthroplasty 2012;27:293–8.
- Ueng SW, Lee CY, Hu CC, Hsieh PH, Chang Y. What is the success of treatment of hip and knee candidal periprosthetic joint infection? Clin Orthop Relat Res 2013;471: 3002–9.
- Dutronc H, Dauchy FA, Cazanave C, Rougie C, Lafarie-Castet S, Couprie B, et al. Candida prosthetic infections: case series and literature review. Scand J Infect Dis 2010;42:890–5.
- Klatte TO, Kendoff D, Kamath AF, Jonen V, Rueger JM, Frommelt L, et al. Single-stage revision for fungal peri-prosthetic joint infection: a single-centre experience. Bone Joint J 2014;96-B:492–6.
- Prazynska M, Gospodarek E. In vitro effect of amphotericin B on Candida albicans, Candida glabrata and Candida parapsilosis biofilm formation. Mycopathologia 2014;177:19–27.
- Shuford JA, Rouse MS, Piper KE, Steckelberg JM, Patel R. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J Infect Dis 2006;194:710–13.
- Arthur RR, Drew RH, Perfect JR. Novel modes of antifungal drug administration. Expert Opin Investig Drugs 2004;13: 903–32.
- Kweon C, McLaren AC, Leon C, McLemore R. Amphotericin B delivery from bone cement increases with porosity but strength decreases. Clin Orthop Relat Res 2011;469:3002–7.
- Denes E, Fiorenza F, Saint-Marcoux F, Megherbi M, Dupon M, Weinbreck P. Voriconazole stability in cement spacers. Med Mal Infect 2012;42:567–8.
- Miller RB, McLaren AC, Pauken C, Clarke HD, McLemore R. Voriconazole is delivered from antifungal-loaded bone cement. Clin Orthop Relat Res 2013;471:195–200.
- Schmidt K, McLaren A, Pauken C, McLemore R. Voriconazole is cytotoxic at locally delivered concentrations: a pilot study. Clin Orthop Relat Res 2013;471:3165–70.
- Delattin N, De Brucker K, Vandamme K, Meert E, Marchand A, Chaltin P, et al. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms. J Antimicrob Chemother 2014;69:1035–44.